Health
Immunotherapy after surgery offers recurrence-free survival advantage for patients with high-risk melanoma – News-Medical.Net
Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either…
Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, will be presented at the ASCO annual meeting June 6, 2021.
Researchers also measured overall survival and found no statistically significant difference in overall survival rates between the two groups of patients…
-
General24 hours agoMitchell Starc fires Ashes warning in Sheffield Shield return as Jake Weatherald and Beau Webster fail to fire
-
General23 hours agoGlobal humanitarian Alison Thompson awarded 2026 Australian of the Year for NSW
-
General11 hours agoOwners barred from Beachport holiday units after council fire safety change
-
Business5 hours agoMonash IVF has named a new Managing Director to help right the ship